



## 1. PRODUCT AND COMPANY INFORMATION


**Distributed By:** WG Critical Care, LLC.  
120 Route 17 North  
Suite 115  
Paramus, NJ 07652 USA

**Product Name:** **CISPLATIN INJECTION**

**Product Code:** 50mg Vial 44567-509-01  
100mg Vial 44567-510-01

**Common / Trade Name:** Cisplatin

**Structure:**



**Chemical Name:** (1) Platinum, diamminedichloro-, (SP-4-2)-; (2) *cis*-Diamminedichloroplatinum.

**Molecular Formula:**  $Cl_2H_6N_2Pt$

**UNII Code:** UNII-Q20Q21Q62J

**CAS Number:** 15663-27-1

**Chemical Family:** Antineoplastic

**Product Use:** Pharmaceutical

**Product Type:** Prescription Drug

**Container Information:** Multi Dose Vials

**General Phone Number:** +1-847-549-3200

**Customer Service Phone Number:** +1-888-493-0861

**Emergency Phone Number:** +1-866-562-4708 (Prosar)

## 2. COMPOSITION / INFORMATION ON INGREDIENTS

<u>Ingredient</u>	<u>Weight %</u>	<u>CAS No.</u>
Cisplatin		15663-27-1

WG Critical Care, LLC.

Cisplatin Injection	Material Safety Data Sheet (MSDS)		
Version: 1.0	Issue Date: August 21, 2013		Page 1 of 6



### 3. HAZARDS IDENTIFICATION

<b>PRIMARY PHYSICAL AND HEALTH HAZARDS:</b>	Potential hazards and adverse reactions are described in the package insert.			
<b>ROUTES OF ENTRY:</b>	Inhalation, ingestion, eye contact, skin contact, injection			
<b>SIGNS &amp; SYMPTOMS OF EXPOSURE:</b>	Adverse events from therapeutic doses include: nephrotoxicity, neuropathies, myelosuppression, fever, infection, nausea, vomiting, ototoxicity, tinnitus, hearing loss, deafness, and vestibular toxicity. Anaphylactic like reactions of facial edema, bronchoconstriction, tachycardia, and hypotension have also been reported. Occupational exposure has not been fully investigated			
<b>CHEMICAL LISTED AS CARCINOGEN:</b>	<table border="0" style="width: 100%;"> <tr> <td style="text-align: center;"><b>NTP: NO</b></td> <td style="text-align: center;"><b>IARC: NO</b></td> <td style="text-align: center;"><b>OSHA: NO</b></td> </tr> </table>	<b>NTP: NO</b>	<b>IARC: NO</b>	<b>OSHA: NO</b>
<b>NTP: NO</b>	<b>IARC: NO</b>	<b>OSHA: NO</b>		

### 4. FIRST AID MEASURES

<b>EYE EXPOSURE:</b>	May cause eye irritation
<b>SKIN EXPOSURE:</b>	May cause skin irritation
<b>INGESTION:</b>	Harmful if swallowed. Gastrointestinal effects (may include nausea, upset stomach, loss of appetite). Renal function effects (may include increased levels of creatinine, BUN, renal failure). Blood effects (may include anemia, neutropenia (decreased number of neutrophils), thrombocytopenia (decreased number of platelets), bone marrow depression). Liver function effects (may include increased levels of SGOT, SGPT, serum LDH, jaundice). Ocular toxicity effects. Electrolyte imbalance. May cause hearing loss.

### 4. FIRST AID MEASURES (continued)

<b>INHALATION:</b>	Not likely under normal use conditions
<b>NOTE TO PHYSICIAN:</b>	See patient package insert in shipping carton for complete information

WG Critical Care, LLC.

Cisplatin Injection	Material Safety Data Sheet (MSDS)
Version: 1.0	Issue Date: August 21, 2013
	Page 2 of 6



#### 5. FIRE FIGHTING MEASURES

<b>FLASH POINT:</b>	Not established
<b>AUTO-IGNITION TEMPERATURE:</b>	Not established
<b>FLAMMABLE LIMITS IN AIR:</b>	Not established
<b>FLAMMABLE LIMITS:</b>	Not established
<b>EXTINGUISHING MEDIA:</b>	Use foam or an all purpose dry chemical to extinguish
<b>UNUSUAL FIRE / EXPLOSION HAZARDS:</b>	Not known

#### 6. ACCIDENTAL RELEASE MEASURE

<b>SPILL: Methods for Cleaning:</b>	If emergency personnel are unavailable, contain spilled material. For small spills add absorbent (soil may be used in the absence of other suitable materials) scoop up material and place in a sealed, liquid-proof container for disposal. For large spills dike spilled material or otherwise contain material to ensure runoff does not reach a waterway. Place spilled material in an appropriate container for disposal
<b>RELEASE TO WATER:</b>	Do not allow release to water

#### 7. HANDLING AND STORAGE

<b>GENERAL HANDLING:</b>	Do not ingest. Wash thoroughly after handling
<b>STORAGE CONDITIONS:</b>	Keep containers tightly closed in a cool well ventilated place. Store between 15-25 <sup>0</sup> C. Do not refrigerate. Protect from Light

WG Critical Care, LLC.

Cisplatin Injection	Material Safety Data Sheet (MSDS)		
Version: 1.0	Issue Date: August 21, 2013		Page 3 of 6



### 8. EXPOSURE CONTROLS / PERSONAL PROTECTION

**RESPIRATORY PROTECTION:** No personal respiratory protective equipment is normally required

**EYE PROTECTION:** Eye protection is only required (safety glasses w/ side shields) during laboratory and manufacturing. Not required for normal final product use.

**VENTILATION** Open handling must be limited. Provide general and/or local exhaust ventilation

**SKIN PROTECTION:** Work uniform and/or laboratory coat. Additional garments should be based on task being performed. Disposable outer garments should be used when there is a potential for contact with the material

### 9. PHYSICAL AND CHEMICAL PROPERTIES

<b>PHYSICAL STATE:</b>	Liquid	<b>SPECIFIC GRAVITY:</b>	Not Available
<b>APPEARANCE AND ODOR:</b>	Aqueous Liquid	<b>EVAPORATION RATE:</b>	Not Available
<b>BOILING POINT:</b>	Not Available	<b>MELTING POINT:</b>	Not Available
<b>VAPOR PRESSURE:</b>	Not Available	<b>SOLUBILITY IN WATER:</b>	Soluble
<b>VAPOR DENSITY:</b>	Not Available	<b>pH:</b>	3.8-5.9

### 10. STABILITY AND REACTIVITY

**STABILITY:** Stable under recommended storage conditions

**INCOMPATIBILITY : (MATERIALS TO AVOID)** Aluminum

**HAZARDOUS POLYMERIZATION:** Not Applicable

**HAZARDOUS DECOMPOSITION:** Not Established

**CONDITIONS TO AVOID:** Not Established

WG Critical Care, LLC.

Cisplatin Injection	Material Safety Data Sheet (MSDS)		
Version: 1.0	Issue Date: August 21, 2013		Page 4 of 6



**11. TOXICOLOGICAL INFORMATION**

**ACUTE TOXICITY**

COMPONENT	TYPE	ROUTE	SPECIES	DOSAGE
Cisplatin	LD <sub>50</sub>	Oral	Rat	25.58mg/kg

**Acute Toxicity:** Gastrointestinal effects (may include nausea, upset stomach, loss of appetite). Renal function effects (may include increased levels of creatinine, BUN, renal failure). Blood effects (may include anemia, neutropenia (decreased number of neutrophils), thrombocytopenia (decreased number of platelets), bone marrow depression). Liver function effects (may include increased levels of SGOT, SGPT, serum LDH, jaundice). Electrolyte imbalance. Ocular toxicity effects. May cause hearing loss. May cause allergic reactions.

**Chronic Toxicity:** Target Organs: Ear. Blood. Kidney. Bone marrow. Nervous system. Skin. Gastrointestinal tract.

**Carcinogenic Effects:** Listed by IARC, NTP. Reasonably anticipated to be a human carcinogen

**Mutagenic Effects:** Considered Mutagenic

**Reproductive Toxicity:** Can impair fertility. Considered fetotoxic.

**FDA Pregnancy Category:** D

**12. ECOLOGICAL INFORMATION**

None Established.

**13. DISPOSAL CONSIDERATIONS**

**Recommend disposal as a hazardous waste**

**WASTE DISPOSAL:** Waste disposal must be in accordance with appropriate Federal, State, and local regulations

**14. TRANSPORT INFORMATION**

**REGULATORY ORGANIZATIONS:**

**DOT:** Not Regulated

**ICAO / IATA:** Not Regulated

**IMO:** Not Regulated

WG Critical Care, LLC.

Cisplatin Injection	Material Safety Data Sheet (MSDS)		
Version: 1.0	Issue Date: August 21, 2013		Page 5 of 6



## 15. REGULATORY INFORMATION

Below is selected regulatory information chosen primarily for possible WG Critical Care use. This section is not a complete analysis or reference to all applicable regulatory information. Please consider all applicable laws and regulations for your city / state / country.

### US Regulations

TSCA – No

CERCLA-No

SARA 302 – No

SARA 313 – No

OSHA Substance Specific - No

## 16. OTHER INFORMATION

As of the date of issuance, we are providing available information relevant to the handling of this material in the workplace. All information contained herein is offered with the good faith belief that it is accurate. THIS MATERIAL SAFETY DATA SHEET SHALL NOT BE DEEMED TO CREATE ANY WARRANTY OF ANY KIND (INCLUDING WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PUROPOSE). In the event of an adverse incident associated with this material, this safety data sheet is not intended to be a substitute for consultation with appropriately trained personnel. Nor is this safety data sheet intended to be a substitute for product literature which may accompany the finished product.

WG Critical Care, LLC.

Cisplatin Injection	Material Safety Data Sheet (MSDS)		
Version: 1.0	Issue Date: August 21, 2013		Page 6 of 6